This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.16255 | DOI Listing |
Publication Analysis
Top Keywords
acute chronic
8
chronic graft-versus-host
8
graft-versus-host disease
8
anztct consensus
4
consensus position
4
position statement
4
statement ruxolitinib
4
ruxolitinib steroid-refractory
4
steroid-refractory acute
4
disease position
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!